Molecular profiling studies have confirmed that breast cancer (BC) represents four distinct subtypes (luminal A, luminal B, Her2+, basal-like) with different underlying biological aberrations [3, 10, 26] and that each major subtype has different prognostic outcomes in terms of patient survival. This evidence concerns the gene ERBB2 and breast cancer.